onlineholdem| Baili Tianheng: BL-B16D1 approved clinical trial for the treatment of advanced solid tumors

News summary

[Baili Tianhengonlineholdem: BL-B16D1 has been approved for clinical trials for the treatment of advanced solid tumors] Securities Times e Company News, Bailitian Heng (688506) announced on the evening of May 9 that the company's independently developed innovative biopharmaceutical BL-B16D1 (dual antibody ADC) has recently received formal approval from the State Food and Drug Administration (NMPA)onlineholdem...

Newsletter text

[Baili Tianheng: BL-B16D1 has been approved for clinical trials for the treatment of advanced solid tumors] Securities Times e Company News, Baili Tianheng (688506) announced on the evening of May 9 that the company's independently developed innovative biopharmaceutical BL-B16D1 (dual antibody ADC), recently received the "Drug Clinical Trial Approval Notice" officially approved and issued by the State Food and Drug Administration (NMPA). The indication for this drug is advanced solid tumors.